🟢 Ironwood Pharmaceuticals is trading 10.85% up in pre-market after raising 2026 revenue and LINZESS guidance

Ironwood Pharmaceuticals is trading at $4.18, up 10.85% in pre-market after raising 2026 guidance.

• Third-quarter results reported November 5 included $133.0 million in revenue and $0.36 GAAP diluted EPS; contemporaneous coverage reported both ahead of consensus estimates.
• Management raised 2026 revenue guidance to $485–$510 million and LINZESS U.S. sales guidance to $1.20–$1.25 billion, citing continued sales growth.
• Broader biotech strength was secondary context.